생체적합성과 표적화를 향상시키기 위해 세포 유래 물질인 엑소좀을 사용하여 기존의 사용 되어지는 대두나 난황으로부터 유래된 리포좀과 비교하여 엑소좀의 우수성을 검증하였다. 엑소좀에 Docetaxel 과 Pluronic 을 사용하여 핵/쉘 구조를 갖는 나노전달체를 제조하였다. 우선 RAW264.7 세포주에서 엑소좀을 분리하였고, 그 후에 Docetaxel 과 Fluronic F-68 을 혼합하고 동결건조를 하여 핵/쉘 구조를 갖는 엑소좀을 형성하였다. Cryo-Transmission Electron Microscopy (...
생체적합성과 표적화를 향상시키기 위해 세포 유래 물질인 엑소좀을 사용하여 기존의 사용 되어지는 대두나 난황으로부터 유래된 리포좀과 비교하여 엑소좀의 우수성을 검증하였다. 엑소좀에 Docetaxel 과 Pluronic 을 사용하여 핵/쉘 구조를 갖는 나노전달체를 제조하였다. 우선 RAW264.7 세포주에서 엑소좀을 분리하였고, 그 후에 Docetaxel 과 Fluronic F-68 을 혼합하고 동결건조를 하여 핵/쉘 구조를 갖는 엑소좀을 형성하였다. Cryo-Transmission Electron Microscopy (TEM), Bio-Transmission Electron Microscopy (TEM) 및 Dynamic Light Scattering (DLS)을 사용하여 엑소좀의 크기와 핵/쉘 구조 형성의 유무를 확인하였고, 유동세포분석 (flow cytometry)를 이용하여 약물 로딩 여부를 확인 할 수 있었다. 또한 방출거동실험을 통하여 엑소좀의 Docetaxel 방출 거동을 살펴보았으며 제어된 방출 거동을 갖는 것으로 입증되었다. 추가적으로 세포독성 실험을 통해 기존의 사용된 리포좀을 이용한 나노입자의 독성을 비교하여 엑소좀의 우수성을 검증하였다
생체적합성과 표적화를 향상시키기 위해 세포 유래 물질인 엑소좀을 사용하여 기존의 사용 되어지는 대두나 난황으로부터 유래된 리포좀과 비교하여 엑소좀의 우수성을 검증하였다. 엑소좀에 Docetaxel 과 Pluronic 을 사용하여 핵/쉘 구조를 갖는 나노전달체를 제조하였다. 우선 RAW264.7 세포주에서 엑소좀을 분리하였고, 그 후에 Docetaxel 과 Fluronic F-68 을 혼합하고 동결건조를 하여 핵/쉘 구조를 갖는 엑소좀을 형성하였다. Cryo-Transmission Electron Microscopy (TEM), Bio-Transmission Electron Microscopy (TEM) 및 Dynamic Light Scattering (DLS)을 사용하여 엑소좀의 크기와 핵/쉘 구조 형성의 유무를 확인하였고, 유동세포분석 (flow cytometry)를 이용하여 약물 로딩 여부를 확인 할 수 있었다. 또한 방출거동실험을 통하여 엑소좀의 Docetaxel 방출 거동을 살펴보았으며 제어된 방출 거동을 갖는 것으로 입증되었다. 추가적으로 세포독성 실험을 통해 기존의 사용된 리포좀을 이용한 나노입자의 독성을 비교하여 엑소좀의 우수성을 검증하였다
Exosomes, which are cell-derived materials, were used as nanoparticles (NPs) containing anticancer agents to enhance biocompatibility and enhance targeting. Exosome-based Core/Shell nanoparticles containing anticancer agents was prepared using Pluronic F-68, which consists of two arms of polyethylen...
Exosomes, which are cell-derived materials, were used as nanoparticles (NPs) containing anticancer agents to enhance biocompatibility and enhance targeting. Exosome-based Core/Shell nanoparticles containing anticancer agents was prepared using Pluronic F-68, which consists of two arms of polyethylene oxide (PEO) as hydrophilic components and one head of polypropylene oxide (PPO) as hydrophobic components. In the present study, we tried to see if these exosome-based Core/Shell nanoparticles are more effective in cancer treatment than conventional liposome-based Core/Shell nanoparticles derived from soybean or egg yolk. First, lyophilization was performed to prepare exosome-based Core/Shell nanoparticles containing drugs, and then conventional liposome-based Core/Shell nanoparticles were prepared in the same manner. The morphology and size distribution of empty exosomes, docetaxel-loaded exosome, and exosome-based Core/Shell nanoparticles were determined using Cryo-Transmission Electron Microscopy (TEM), Bio-Transmission Electron Microscopy (TEM) and Dynamic Light Scattering (DLS). The amount of protein expression was performed by western blot analysis to observe the activity of the lyophilized exosomes. The flow cytometry was used to evaluate if the drug had entered the exosomes. Time-dependent release behavior of Core/Shell nanoparticles was monitored using the dialysis bag in vitro. In WST-1 assay, we found that exosomes were not toxic and work more efficiently than liposomes. The results showed that the size and polydispersity index (PDI) of the exosome-based Core/Shell nanoparticles were much more stable than the liposome-based Core/Shell nanoparticles, and proved to have a more effectively controlled release behavior. In conclusion, we suggest that exosomes are more suitable as vesicles for drug delivery than liposomes.
Exosomes, which are cell-derived materials, were used as nanoparticles (NPs) containing anticancer agents to enhance biocompatibility and enhance targeting. Exosome-based Core/Shell nanoparticles containing anticancer agents was prepared using Pluronic F-68, which consists of two arms of polyethylene oxide (PEO) as hydrophilic components and one head of polypropylene oxide (PPO) as hydrophobic components. In the present study, we tried to see if these exosome-based Core/Shell nanoparticles are more effective in cancer treatment than conventional liposome-based Core/Shell nanoparticles derived from soybean or egg yolk. First, lyophilization was performed to prepare exosome-based Core/Shell nanoparticles containing drugs, and then conventional liposome-based Core/Shell nanoparticles were prepared in the same manner. The morphology and size distribution of empty exosomes, docetaxel-loaded exosome, and exosome-based Core/Shell nanoparticles were determined using Cryo-Transmission Electron Microscopy (TEM), Bio-Transmission Electron Microscopy (TEM) and Dynamic Light Scattering (DLS). The amount of protein expression was performed by western blot analysis to observe the activity of the lyophilized exosomes. The flow cytometry was used to evaluate if the drug had entered the exosomes. Time-dependent release behavior of Core/Shell nanoparticles was monitored using the dialysis bag in vitro. In WST-1 assay, we found that exosomes were not toxic and work more efficiently than liposomes. The results showed that the size and polydispersity index (PDI) of the exosome-based Core/Shell nanoparticles were much more stable than the liposome-based Core/Shell nanoparticles, and proved to have a more effectively controlled release behavior. In conclusion, we suggest that exosomes are more suitable as vesicles for drug delivery than liposomes.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.